Supplemental tables

Supplemental Table 1. Diagnostic Testing Performed Prior to Florbetapir Amyloid PET Scan

	AUC			*Non-AUC*		
	Group A (n=65)	*Group B (n=60)*	*All (n=125)*	*Group A (n=45)*	*Group B (n=59)*	*All (n=104)*
Neuropsy Testing	49 (75.4%)	25 (41.7%)	74 (59.2%)	37 (82.2%)	27 (45.8%)	64 (61.5%)
Brain Structural Imaging (CT/MRI)	63 (96.9%)	30 (50.0%)	93 (74.4%)	42 (93.3%)	19 (32.2%)	61 (58.7%)
Lumbar Puncture	5 (7.7%)	5 (8.3%)	10 (8.0%)	3 (6.7%)	1 (1.7%)	4 (3.8%)
FDG PET	10 (15.4%)	6 (10.0%)	16 (12.8%)	4 (8.9%)		4 (3.8%)
ApoE	19 (29.2%)	10 (16.7%)	29 (23.2%)	9 (20.0%)	4 (6.8%)	13 (12.5%)
Lab Tests(CBC/Serum Chemistry/Urinalysis)	38 (58.5%)	22 (36.7%)	60 (48.0%)	21 (46.7%)	21 (35.6%)	42 (40.4%)

Supplemental Table 2. Detailed change in diagnosis after receipt of florbetapir scan results

AUC like	Prescan diagnosis	Postscan Diagnosis			Change in Diagnosis
		Due to AD	Indeterminate	Not due to AD	
All subjects (n=125)	Due to AD: Atypical AD (n=10)	7 (70.0%)	0 (0.0%)	3 (30.0%)	3/10 (30.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=3)	1 (33.3%)	0 (0.0%)	2 (66.7%)	2/3 (66.7%)
	Due to AD: Mixed Dementia with AD (n=8)	6 (75.0%)	0 (0.0%)	2 (25.0%)	2/8 (25.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiology (n=98)	40 (40.8%)	31 (31.6%)	27 (27.6%)	67/98 (68.4%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=6)	4 (66.7%)	0 (0.0%)	2 (33.3%)	4/6 (66.7%)
	Total	**58 (46%)**	**31 (25%)**	**36 (29%)**	**78 (62%)**
Amyloid-negative subjects (N=66)	Due to AD: Atypical AD (n=3)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3/3 (100.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=2)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2/2 (100.0%)
	Due to AD: Mixed Dementia with AD (n=2)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2/2 (100.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiology, (n=57)	0 (0.0%)	30 (52.6%)	27 (47.4%)	27/57 (47.4%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=2)	0 (0.0%)	0 (0.0%)	2 (100.0%)	0/2 (0.0%)
Amyloid-positive subjects (N=59)	Due to AD: Atypical AD (n=7)	7 (100.0%)	0 (0.0%)	0 (0.0%)	0/7 (0.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=1)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0/1 (0.0%)
	Due to AD: Mixed Dementia with AD (n=6)	6 (100.0%)	0 (0.0%)	0 (0.0%)	0/6 (0.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiology, (n=41)	40 (97.6%)	1 (2.4%)	0 (0.0%)	40/41 (97.6%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=4)	4 (100.0%)	0 (0.0%)	0 (0.0%)	4/4 (100.0%)

Supplemental Table 3. Overall Change in Management Plan

	% Management Plan Changed			
	Total	**Group A**	**Group B**	**p Group A vs Group B**
AUC	88.00	78.46	98.33	0.0006
NonAUC	85.58	77.78	91.53	0.0884
Total	86.90	78.18	94.96	0.0002

Formatted: Centered

Formatted: Centered

Formatted: Centered

Supplemental Table 4. Change in Management Plan Items in Group B Subjects as a Function of PET Amyloid Status and AUC Classification

Deleted: 3

	Physican Management Plan	*Added to Management Plan*	*Removed from Management Plan*	*Pre-scan Yes/ Post-scan Yes*	*Pre-scan No/ Post-scan No*	*Change: Added or removed from the Management Plan*	*Included in Management Plan Pre Scan*	*Included in Management Plan Post Scan*
All Group B AUC subjects (N=60)	Brain Structural Imaging (CT/MRI)	1 (1.7%)	18 (30.0%)	10 (16.7%)	31 (51.7%)	**19 (31.7%)**	28 (46.7%)	11 (18.3%)
	Lumbar puncture	0 (0.00%)	14 (23.3%)	0 (0.00%)	46 (76.7%)	**14 (23.3%)**	14 (23.3%)	0 (0.00%)
	Neuropsy Testing (brief/extensive)	2 (3.3%)	25 (41.7%)	7 (11.7%)	26 (43.3%)	**27 (45.0%)**	32 (53.3%)	9 (15.0%)
	FDG PET	1 (1.7%)	13 (21.7%)	1 (1.7%)	45 (75.0%)	**14 (23.3%)**	14 (23.3%)	2 (3.3%)
	Apolipoprotein E testing	0 (0.00%)	3 (5.0%)	2 (3.3%)	55 (91.7%)	**3 (5.0%)**	5 (8.3%)	2 (3.3%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.00%)	11 (18.3%)	8 (13.3%)	41 (68.3%)	**11 (18.3%)**	19 (31.7%)	8 (13.3%)
	Refer to a clinical trial for AD or early AD	4 (6.7%)	3 (5.0%)	1 (1.7%)	52 (86.7%)	**7 (11.7%)**	4 (6.7%)	5 (8.3%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	14 (23.3%)	13 (21.7%)	17 (28.3%)	16 (26.7%)	**27 (45.0%)**	30 (50.0%)	31 (51.7%)
All Group B Non-AUC subjects (N=59)	Brain Structural Imaging (CT/MRI)	0 (0.00%)	12 (20.3%)	16 (27.1%)	31 (52.5%)	**12 (20.3%)**	28 (47.5%)	16 (27.1%)
	Lumbar puncture	1 (1.7%)	5 (8.5%)	0 (0.00%)	53 (89.8%)	**6 (10.2%)**	5 (8.5%)	1 (1.7%)
	Neuropsy Testing (brief/extensive)	2 (3.4%)	18 (30.5%)	10 (16.9%)	29 (49.2%)	**20 (33.9%)**	28 (47.5%)	12 (20.3%)
	FDG PET	0 (0.00%)	9 (15.3%)	0 (0.00%)	50 (84.7%)	**9 (15.3%)**	9 (15.3%)	0 (0.00%)
	Apolipoprotein E testing	2 (3.4%)	6 (10.2%)	3 (5.1%)	48 (81.4%)	**8 (13.6%)**	9 (15.3%)	5 (8.5%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	2 (3.4%)	4 (6.8%)	22 (37.3%)	31 (52.5%)	**6 (10.2%)**	26 (44.1%)	24 (40.7%)
	Refer to a clinical trial for AD or early AD	6 (10.2%)	5 (8.5%)	0 (0.00%)	48 (81.4%)	**11 (18.6%)**	5 (8.5%)	6 (10.2%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	7 (11.9%)	9 (15.3%)	26 (44.1%)	17 (28.8%)	**16 (27.1%)**	35 (59.3%)	33 (55.9%)

	Physican Management Plan	*Added to Management Plan*	*Removed from Management Plan*	*Pre-scan Yes/ Post-scan Yes*	*Pre-scan No/ Post-scan No*	*Change: Added or removed from the Management Plan*	*Included in Management Plan Pre Scan*	*Included in Management Plan Post Scan*
Group B AUC AB+ subjects (N=30)	Brain Structural Imaging (CT/MRI)	0 (0.00%)	11 (36.7%)	4 (13.3%)	15 (50.0%)	**11 (36.7%)**	15 (50.0%)	4 (13.3%)
	Lumbar puncture	0 (0.00%)	7 (23.3%)	0 (0.00%)	23 (76.7%)	**7 (23.3%)**	7 (23.3%)	0 (0.00%)
	Neuropsy Testing (brief/extensive)	0 (0.00%)	14 (46.7%)	2 (6.7%)	14 (46.7%)	**14 (46.7%)**	16 (53.3%)	2 (6.7%)
	FDG PET	0 (0.00%)	7 (23.3%)	0 (0.00%)	23 (76.7%)	**7 (23.3%)**	7 (23.3%)	0 (0.00%)
	Apolipoprotein E testing	0 (0.00%)	2 (6.7%)	2 (6.7%)	26 (86.7%)	**2 (6.7%)**	4 (13.3%)	2 (6.7%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.00%)	6 (20.0%)	3 (10.0%)	21 (70.0%)	**6 (20.0%)**	9 (30.0%)	3 (10.0%)
	Refer to a clinical trial for AD or early AD	4 (13.3%)	1 (3.3%)	1 (3.3%)	24 (80.0%)	**5 (16.7%)**	2 (6.7%)	5 (16.7%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	13 (43.3%)	1 (3.3%)	13 (43.3%)	3 (10.0%)	**14 (46.7%)**	14 (46.7%)	26 (86.7%)
Group B Non-AUC AB+ subjects (N=24)	Brain Structural Imaging (CT/MRI)	0 (0.00%)	6 (25.0%)	5 (20.8%)	13 (54.2%)	**6 (25.0%)**	11 (45.8%)	5 (20.8%)
	Lumbar puncture	0 (0.00%)	3 (12.5%)	0 (0.00%)	21 (87.5%)	**3 (12.5%)**	3 (12.5%)	0 (0.00%)
	Neuropsy Testing (brief/extensive)	1 (4.2%)	10 (41.7%)	1 (4.2%)	12 (50.0%)	**11 (45.8%)**	11 (45.8%)	2 (8.3%)
	FDG PET	0 (0.00%)	5 (20.8%)	0 (0.00%)	19 (79.2%)	**5 (20.8%)**	5 (20.8%)	0 (0.00%)
	Apolipoprotein E testing	1 (4.2%)	2 (8.3%)	1 (4.2%)	20 (83.3%)	**3 (12.5%)**	3 (12.5%)	2 (8.3%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	2 (8.3%)	3 (12.5%)	8 (33.3%)	11 (45.8%)	**5 (20.8%)**	11 (45.8%)	10 (41.7%)
	Refer to a clinical trial for AD or early AD	6 (25.0%)	1 (4.2%)	0 (0.00%)	17 (70.8%)	**7 (29.2%)**	1 (4.2%)	6 (25.0%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	5 (20.8%)	2 (8.3%)	17 (70.8%)	0 (0.00%)	**7 (29.2%)**	19 (79.2%)	22 (91.7%)

Group B AUC AB- subjects (N=30)	Brain Structural Imaging (CT/MRI)	1 (3.3%)	7 (23.3%)	6 (20.0%)	16 (53.3%)	**8 (26.7%)**	13 (43.3%)	7 (23.3%)
	Lumbar puncture	0 (0.00%)	7 (23.3%)	0 (0.00%)	23 (76.7%)	**7 (23.3%)**	7 (23.3%)	0 (0.00%)
	Neuropsy Testing (brief/extensive)	2 (6.7%)	11 (36.7%)	5 (16.7%)	12 (40.0%)	**13 (43.3%)**	16 (53.3%)	7 (23.3%)
	FDG PET	1 (3.3%)	6 (20.0%)	1 (3.3%)	22 (73.3%)	**7 (23.3%)**	7 (23.3%)	2 (6.7%)
	Apolipoprotein E testing	0 (0.00%)	1 (3.3%)	0 (0.00%)	29 (96.7%)	**1 (3.3%)**	1 (3.3%)	0 (0.00%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.00%)	5 (16.7%)	5 (16.7%)	20 (66.7%)	**5 (16.7%)**	10 (33.3%)	5 (16.7%)
	Refer to a clinical trial for AD or early AD	0 (0.00%)	2 (6.7%)	0 (0.00%)	28 (93.3%)	**2 (6.7%)**	2 (6.7%)	0 (0.00%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	1 (3.3%)	12 (40.0%)	4 (13.3%)	13 (43.3%)	**13 (43.3%)**	16 (53.3%)	5 (16.7%)
Group B Non-AUC AB- subjects (N=35)	Brain Structural Imaging (CT/MRI)	0 (0.00%)	6 (17.1%)	11 (31.4%)	18 (51.4%)	**6 (17.1%)**	17 (48.6%)	11 (31.4%)
	Lumbar puncture	1 (2.9%)	2 (5.7%)	0 (0.00%)	32 (91.4%)	**3 (8.6%)**	2 (5.7%)	1 (2.9%)
	Neuropsy Testing (brief/extensive)	1 (2.9%)	8 (22.9%)	9 (25.7%)	17 (48.6%)	**9 (25.7%)**	17 (48.6%)	10 (28.6%)
	FDG PET	0 (0.00%)	4 (11.4%)	0 (0.00%)	31 (88.6%)	**4 (11.4%)**	4 (11.4%)	0 (0.00%)
	Apolipoprotein E testing	1 (2.9%)	4 (11.4%)	2 (5.7%)	28 (80.0%)	**5 (14.3%)**	6 (17.1%)	3 (8.6%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.00%)	1 (2.9%)	14 (40.0%)	20 (57.1%)	**1 (2.9%)**	15 (42.9%)	14 (40.0%)
	Refer to a clinical trial for AD or early AD	0 (0.00%)	4 (11.4%)	0 (0.00%)	31 (88.6%)	**4 (11.4%)**	4 (11.4%)	0 (0.00%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	2 (5.7%)	7 (20.0%)	9 (25.7%)	17 (48.6%)	**9 (25.7%)**	16 (45.7%)	11 (31.4%)

Supplemental Table 5. Change in Diagnosis After Florbetapir PET in Subjects with Prescan Structural Imaging (MRI or CT) as per IIWG AUC

Deleted: 4

AUC like	Prescan diagnosis	Postscan Diagnosis			Change in Diagnosis
		Due to AD	Indeterminate	Not due to AD	
All subjects (n=93)	Due to AD: Atypical AD (n=10)	7 (70.0%)	0 (0.0%)	3 (30.0%)	3/10 (30.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=2)	1 (50.0%)	0 (0.0%)	1 (50.0%)	1/2 (50.0%)
	Due to AD: Mixed Dementia with AD (n=7)	5 (71.4%)	0 (0.0%)	2 (28.6%)	2/7 (28.6%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiologyt (n=69)	23 (33.3%)	21 (30.4%)	25 (36.2%)	48/69 (69.6%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=5)	3 (60.0%)	0 (0.0%)	2 (40.0%)	3/5 (60.0%)
	Total	**39 (41.9%)**	**21 (22.6%)**	**33 (35.5%)**	**57 (61.3%)**
Amyloid-negative subjects (N=53)	Due to AD: Atypical AD (n=3)	0 (0.0%)	0 (0.0%)	3 (100.0%)	3/3 (100.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=1)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1/1 (100.0%)
	Due to AD: Mixed Dementia with AD (n=2)	0 (0.0%)	0 (0.0%)	2 (100.0%)	2/2 (100.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiology (n=45)	0 (0.0%)	20 (44.4%)	25 (55.6%)	25/45 (55.6%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=2)	0 (0.0%)	0 (0.0%)	2 (100.0%)	0/2 (0.0%)
Amyloid-positive subjects (N=40)	Due to AD: Atypical AD (n=7)	7 (100.0%)	0 (0.0%)	0 (0.0%)	0/7 (0.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=1)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0/1 (0.0%)
	Due to AD: Mixed Dementia with AD (n=5)	5 (100.0%)	0 (0.0%)	0 (0.0%)	0/5 (0.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiologyt (n=24)	23 (95.8%)	1 (4.2%)	0 (0.0%)	23/24 (95.8%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=3)	3 (100.0%)	0 (0.0%)	0 (0.0%)	3/3 (100.0%)

Non AUC like	Prescan diagnosis	Postscan Diagnosis			Change in Diagnosis
		Due to AD	Indeterminate	Not due to AD	
All subjects (n=136)	Due to AD: Probable/typical AD (n=30)	23 (76.7%)	6 (20.0%)	1 (3.3%)	7/30 (23.3%)
	Due to AD: MCI-AD/Prodromal AD (n=35)	17 (48.6%)	16 (45.7%)	2 (5.7%)	18/35 (51.4%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=1)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1/1 (100.0%)
	Due to AD: Mixed Dementia with AD (n=1)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0/1 (0.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiologyt (n=53)	24 (45.3%)	21 (39.6%)	8 (15.1%)	32/53 (60.4%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=16)	9 (56.3%)	1 (6.3%)	6 (37.5%)	10/16 (62.5%)
	Total	**74 (54.4%)**	**44 (32.4%)**	**18 (13.2%)**	**68 (50.0%)**
Amyloid-negative subjects (N=63)	Due to AD: Probable/typical AD (n=8)	1 (12.5%)	6 (75.0%)	1 (12.5%)	7/8 (87.5%)
	Due to AD: MCI-AD/Prodromal AD (n=18)	0 (0.0%)	16 (88.9%)	2 (11.1%)	18/18 (100.0%)
	Due to AD: Lewy Body Disease with AD (amyloid) pathology (n=1)	0 (0.0%)	0 (0.0%)	1 (100.0%)	1/1 (100.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiologyt (n=29)	0 (0.0%)	21 (72.4%)	8 (27.6%)	8/29 (27.6%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=7)	0 (0.0%)	1 (14.3%)	6 (85.7%)	1/7 (14.3%)
Amyloid-positive subjects (N=73)	Due to AD: Probable/typical AD (n=22)	22 (100.0%)	0 (0.0%)	0 (0.0%)	0/22 (0.0%)
	Due to AD: MCI-AD/Prodromal AD (n=17)	17 (100.0%)	0 (0.0%)	0 (0.0%)	0/17 (0.0%)
	Due to AD: Mixed Dementia with AD (n=1)	1 (100.0%)	0 (0.0%)	0 (0.0%)	0/1 (0.0%)
	Indeterminate: Dementia, MCI or cognitive decline with uncertain etiologyt (n=24)	24 (100.0%)	0 (0.0%)	0 (0.0%)	24/24 (100.0%)
	Not due to AD: Dementia or impairment with non AD working diagnosis (n=9)	9 (100.0%)	0 (0.0%)	0 (0.0%)	9/9 (100.0%)

Supplemental Table 6. Change in Management Plan Items in Group B Subjects as a Function of PET Amyloid Status and AUC Classification in Subjects with Prescan Structural Imaging (MRI or CT) as per IIWG

Deleted: 5

	Physican Management Plan	*Added to Management Plan*	*Removed from Management Plan*	*Pre-scan Yes/ Post-scan Yes*	*Pre-scan No/ Post-scan No*	*Added or removed from the Management Plan*	*Included in Management Plan Pre Scan*	*Included in Management Plan Post Scan*
All Group B AUC subjects (N=30)	Brain Structural Imaging (CT/MRI)	0 (0.0%)	5 (16.7%)	0 (0.0%)	25 (83.3%)	5 (16.7%)	5 (16.7%)	0 (0.0%)
	Lumbar puncture	0 (0.0%)	13 (43.3%)	0 (0.0%)	17 (56.7%)	13 (43.3%)	13 (43.3%)	0 (0.0%)
	Neuropsy Testing (brief/extensive)	0 (0.0%)	15 (50.0%)	4 (13.3%)	11 (36.7%)	15 (50.0%)	19 (63.3%)	4 (13.3%)
	FDG PET	0 (0.0%)	11 (36.7%)	0 (0.0%)	19 (63.3%)	11 (36.7%)	11 (36.7%)	0 (0.0%)
	Apolipoprotein E testing	0 (0.0%)	2 (6.7%)	1 (3.3%)	27 (90.0%)	2 (6.7%)	3 (10.0%)	1 (3.3%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.0%)	3 (10.0%)	1 (3.3%)	26 (86.7%)	3 (10.0%)	4 (13.3%)	1 (3.3%)
	Refer to a clinical trial for AD or early AD	2 (6.7%)	3 (10.0%)	1 (3.3%)	24 (80.0%)	5 (16.7%)	4 (13.3%)	3 (10.0%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	6 (20.0%)	7 (23.3%)	5 (16.7%)	12 (40.0%)	13 (43.3%)	12 (40.0%)	11 (36.7%)
All Group B Non-AUC subjects (N=89)	Brain Structural Imaging (CT/MRI)	1 (1.1%)	25 (28.1%)	26 (29.2%)	37 (41.6%)	26 (29.2%)	51 (57.3%)	27 (30.3%)
	Lumbar puncture	1 (1.1%)	6 (6.7%)	0 (0.0%)	82 (92.1%)	7 (7.9%)	6 (6.7%)	1 (1.1%)
	Neuropsy Testing (brief/extensive)	4 (4.5%)	28 (31.5%)	13 (14.6%)	44 (49.4%)	32 (36.0%)	41 (46.1%)	17 (19.1%)
	FDG PET	1 (1.1%)	11 (12.4%)	1 (1.1%)	76 (85.4%)	12 (13.5%)	12 (13.5%)	2 (2.2%)
	Apolipoprotein E testing	2 (2.2%)	7 (7.9%)	4 (4.5%)	76 (85.4%)	9 (10.1%)	11 (12.4%)	6 (6.7%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	2 (2.2%)	12 (13.5%)	29 (32.6%)	46 (51.7%)	14 (15.7%)	41 (46.1%)	31 (34.8%)
	Refer to a clinical trial for AD or early AD	8 (9.0%)	5 (5.6%)	0 (0.0%)	76 (85.4%)	13 (14.6%)	5 (5.6%)	8 (9.0%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	15 (16.9%)	15 (16.9%)	38 (42.7%)	21 (23.6%)	30 (33.7%)	53 (59.6%)	53 (59.6%)

	Physican Management Plan	*Added to Management Plan*	*Removed from Management Plan*	*Pre-scan Yes/ Post-scan Yes*	*Pre-scan No/ Post-scan No*	*Added or removed from the Management Plan*	*Included in Management Plan Pre Scan*	*Included in Management Plan Post Scan*
Group B AUC AB+ subjects (N=11)	Brain Structural Imaging (CT/MRI)	0 (0.0%)	1 (9.1%)	0 (0.0%)	10 (90.9%)	1 (9.1%)	1 (9.1%)	0 (0.0%)
	Lumbar puncture	0 (0.0%)	6 (54.5%)	0 (0.0%)	5 (45.5%)	6 (54.5%)	6 (54.5%)	0 (0.0%)
	Neuropsy Testing (brief/extensive)	0 (0.0%)	5 (45.5%)	1 (9.1%)	5 (45.5%)	5 (45.5%)	6 (54.5%)	1 (9.1%)
	FDG PET	0 (0.0%)	5 (45.5%)	0 (0.0%)	6 (54.5%)	5 (45.5%)	5 (45.5%)	0 (0.0%)
	Apolipoprotein E testing	0 (0.0%)	1 (9.1%)	1 (9.1%)	9 (81.8%)	1 (9.1%)	2 (18.2%)	1 (9.1%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (100.0%)			0 (0.0%)
	Refer to a clinical trial for AD or early AD	2 (18.2%)	1 (9.1%)	1 (9.1%)	7 (63.6%)	3 (27.3%)	2 (18.2%)	3 (27.3%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	6 (54.5%)	0 (0.0%)	4 (36.4%)	1 (9.1%)	6 (54.5%)	4 (36.4%)	10 (90.9%)
Group B Non-AUC AB+ subjects (N=43)	Brain Structural Imaging (CT/MRI)	0 (0.0%)	16 (37.2%)	9 (20.9%)	18 (41.9%)	16 (37.2%)	25 (58.1%)	9 (20.9%)
	Lumbar puncture	0 (0.0%)	4 (9.3%)	0 (0.0%)	39 (90.7%)	4 (9.3%)	4 (9.3%)	0 (0.0%)
	Neuropsy Testing (brief/extensive)	1 (2.3%)	19 (44.2%)	2 (4.7%)	21 (48.8%)	20 (46.5%)	21 (48.8%)	3 (7.0%)
	FDG PET	0 (0.0%)	7 (16.3%)	0 (0.0%)	36 (83.7%)	7 (16.3%)	7 (16.3%)	0 (0.0%)
	Apolipoprotein E testing	1 (2.3%)	3 (7.0%)	2 (4.7%)	37 (86.0%)	4 (9.3%)	5 (11.6%)	3 (7.0%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	2 (4.7%)	9 (20.9%)	11 (25.6%)	21 (48.8%)	11 (25.6%)	20 (46.5%)	13 (30.2%)
	Refer to a clinical trial for AD or early AD	8 (18.6%)	1 (2.3%)	0 (0.0%)	34 (79.1%)	9 (20.9%)	1 (2.3%)	8 (18.6%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	12 (27.9%)	3 (7.0%)	26 (60.5%)	2 (4.7%)	15 (34.9%)	29 (67.4%)	38 (88.4%)

Group B AUC AB- subjects (N=19)	Brain Structural Imaging (CT/MRI)	0 (0.0%)	4 (21.1%)	0 (0.0%)	15 (78.9%)	4 (21.1%)	4 (21.1%)	0 (0.0%)
	Lumbar puncture	0 (0.0%)	7 (36.8%)	0 (0.0%)	12 (63.2%)	7 (36.8%)	7 (36.8%)	0 (0.0%)
	Neuropsy Testing (brief/extensive)	0 (0.0%)	10 (52.6%)	3 (15.8%)	6 (31.6%)	10 (52.6%)	13 (68.4%)	3 (15.8%)
	FDG PET	0 (0.0%)	6 (31.6%)	0 (0.0%)	13 (68.4%)	6 (31.6%)	6 (31.6%)	0 (0.0%)
	Apolipoprotein E testing	0 (0.0%)	1 (5.3%)	0 (0.0%)	18 (94.7%)	1 (5.3%)	1 (5.3%)	0 (0.0%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.0%)	3 (15.8%)	1 (5.3%)	15 (78.9%)	3 (15.8%)	4 (21.1%)	1 (5.3%)
	Refer to a clinical trial for AD or early AD	0 (0.0%)	2 (10.5%)	0 (0.0%)	17 (89.5%)	2 (10.5%)	2 (10.5%)	0 (0.0%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	0 (0.0%)	7 (36.8%)	1 (5.3%)	11 (57.9%)	7 (36.8%)	8 (42.1%)	1 (5.3%)
Group B Non-AUC AB- subjects (N=46)	Brain Structural Imaging (CT/MRI)	1 (2.2%)	9 (19.6%)	17 (37.0%)	19 (41.3%)	10 (21.7%)	26 (56.5%)	18 (39.1%)
	Lumbar puncture	1 (2.2%)	2 (4.3%)	0 (0.0%)	43 (93.5%)	3 (6.5%)	2 (4.3%)	1 (2.2%)
	Neuropsy Testing (brief/extensive)	3 (6.5%)	9 (19.6%)	11 (23.9%)	23 (50.0%)	12 (26.1%)	20 (43.5%)	14 (30.4%)
	FDG PET	1 (2.2%)	4 (8.7%)	1 (2.2%)	40 (87.0%)	5 (10.9%)	5 (10.9%)	2 (4.3%)
	Apolipoprotein E testing	1 (2.2%)	4 (8.7%)	2 (4.3%)	39 (84.8%)	5 (10.9%)	6 (13.0%)	3 (6.5%)
	Lab Tests(CBC/Serum Chemistry/Urinalysis)	0 (0.0%)	3 (6.5%)	18 (39.1%)	25 (54.3%)	3 (6.5%)	21 (45.7%)	18 (39.1%)
	Refer to a clinical trial for AD or early AD	0 (0.0%)	4 (8.7%)	0 (0.0%)	42 (91.3%)	4 (8.7%)	4 (8.7%)	0 (0.0%)
	Give a trial of an acetylcholinesterase inhibitor or memantine	3 (6.5%)	12 (26.1%)	12 (26.1%)	19 (41.3%)	15 (32.6%)	24 (52.2%)	15 (32.6%)